Sven Norbert Reske

Sven Norbert Reske's AcademicInfluence.com Rankings

Sven Norbert Reske

Engineering

#6919

World Rank

#8274

Historical Rank

Biomedical Engineering

#653

World Rank

#663

Historical Rank

engineering Degrees

Sven Norbert Reske

Philosophy

#9269

World Rank

#12803

Historical Rank

Logic

#6253

World Rank

#7754

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

Sven Norbert Reske's Degrees

Doctorate Medicine Stanford University

Why Is Sven Norbert Reske Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sven Norbert Reske's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. (2007) (1335)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study (2003) (828)
Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. (2003) (423)
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. (2005) (369)
Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. (1999) (352)
Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. (1997) (320)
Extranodal malignant lymphoma: detection with FDG PET versus CT. (1998) (320)
FDG-PET for clinical use (2001) (317)
Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. (2001) (291)
18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. (1998) (290)
FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters (2002) (280)
Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma” (2013) (275)
Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. (1999) (275)
Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures (2001) (243)
Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. (1998) (241)
3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. (2002) (238)
2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma (2001) (236)
Experience with carbon-11 choline positron emission tomography in prostate carcinoma (2000) (227)
Imaging prostate cancer with 11C-choline PET/CT. (2006) (222)
Gene silencing by adenovirus‐delivered siRNA (2003) (219)
Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. (1998) (217)
FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. (1998) (212)
Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. (1998) (212)
The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. (2011) (210)
Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. (1999) (208)
Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. (2001) (206)
New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. (2016) (202)
Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. (2007) (200)
Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. (2002) (199)
FTDP‐17: An early‐onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation (1999) (190)
Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. (1995) (186)
Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD (2005) (184)
131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging (2003) (182)
3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. (2003) (181)
Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. (2000) (180)
Initial results in the assessment of multiple myeloma using 18F-FDG PET (2002) (180)
FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. (1999) (174)
Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. (1997) (172)
Values and Limitations of 18F-Fluorodeoxyglucose–Positron-Emission Tomography with Preoperative Evaluation of Patients with Pancreatic Masses (2000) (172)
Molecular imaging of proliferation in malignant lymphoma. (2006) (169)
Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT (2009) (169)
[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy (2007) (168)
Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer (2002) (165)
2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. (1995) (164)
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. (2001) (160)
Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer (2003) (159)
Detection of liver metastases from pancreatic cancer using FDG PET. (1999) (154)
Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET). (1997) (153)
FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. (2001) (151)
Structured treatment interruption in patients with alveolar echinococcosis (2004) (149)
Evaluation of [11C]‐choline positron‐emission/computed tomography in patients with increasing prostate‐specific antigen levels after primary treatment for prostate cancer (2007) (140)
Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. (2000) (138)
In vivo imaging of activated microglia using [11 C]PK11195 and positron emission tomography in patients after ischemic stroke (2000) (138)
Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. (2012) (120)
Is 18F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? (2000) (119)
Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2 (2010) (111)
Dissociating a Common Working Memory Network from Different Neural Substrates of Phonological and Spatial Stimulus Processing (2002) (111)
Positron emission tomography (PET) for staging of solitary plasmacytoma. (2003) (110)
Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? (1999) (109)
Biological characterisation of breast cancer by means of PET (2004) (109)
Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? (2001) (101)
Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience. (2007) (101)
131I/123I-Metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging (2003) (99)
Clinical relevance of imaging proliferative activity in lung nodules (2005) (94)
Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. (1999) (93)
FDG-PET: procedure guidelines for tumour imaging (2003) (93)
[Positron emission tomography in diagnosis of renal cell carcinoma]. (1996) (90)
Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. (1999) (90)
[11C]Choline PET/CT for Targeted Salvage Lymph Node Dissection in Patients with Biochemical Recurrence after Primary Curative Therapy for Prostate Cancer (2008) (83)
Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma (1999) (83)
Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. (2007) (83)
188Re or 90Y‐labelled anti‐CD66 antibody as part of a dose‐reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I–II study (2005) (81)
Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) in pancreatic cancer cell lines (2002) (80)
RADIOIMMUNOIMAGING FOR DIAGNOSIS OF BONE MARROW INVOLVEMENT IN BREAST CANCER AND MALIGNANT LYMPHOMA (1989) (79)
Is a preoperative multidiagnostic approach to predict surgical resectability of periampullary tumors still effective? (2001) (78)
Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. (2010) (76)
Breast scintigraphy: procedure guidelines for tumour imaging (2003) (74)
Intracoronary β-Irradiation With a Liquid 188Re-Filled Balloon Six-Month Results From a Clinical Safety and Feasibility Study (2000) (74)
Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: A 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study (2008) (71)
Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours (2006) (71)
Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine (2008) (68)
Bone scintigraphy: procedure guidelines for tumour imaging (2003) (68)
Cranial Neuronavigation with Direct Integration of 11C Methionine Positron Emission Tomography (PET) Data – Results of a Pilot Study in 32 Surgical Cases (2002) (67)
Cost-Effectiveness of Hybrid PET/CT for Staging of Non–Small Cell Lung Cancer (2010) (66)
PET and restaging of malignant lymphoma including residual masses and relapse (2003) (64)
Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT (2007) (64)
[11C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy (2009) (63)
First Demonstration of Leukemia Imaging with the Proliferation Marker 18F-Fluorodeoxythymidine (2008) (62)
15(p-[123I]Iodophenyl)pentadecanoic acid as tracer of lipid metabolism: comparison with [1-14C]palmitic acid in murine tissues. (1984) (62)
Synthesis, characterization, and biodistribution of multiple 89Zr-labeled pore-expanded mesoporous silica nanoparticles for PET. (2014) (62)
Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma (2010) (59)
PTEN mutation: many birds with one stone in tumorigenesis. (2008) (59)
Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. (2001) (57)
11C‐Choline positron‐emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer (2007) (56)
S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version (2013) (55)
Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia (1999) (54)
Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases. (2012) (53)
Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk? (2002) (52)
[11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy (2008) (51)
Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography (2000) (51)
Delusional infestation: Neural correlates and antipsychotic therapy investigated by multimodal neuroimaging (2010) (50)
Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration (2004) (49)
Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation (2001) (47)
Pharmacokinetics of 99Tcm-pertechnetate and 188Re-perrhenate after oral administration of perchlorate: option for subsequent care after the use of liquid 188Re in a balloon catheter. (1998) (47)
[18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study. (2004) (46)
Intracoronary &bgr;‐Irradiation With a Rhenium‐188‐Filled Balloon Catheter: A Randomized Trial in Patients With De Novo and Restenotic Lesions (2003) (46)
Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs. (2000) (46)
How useful is positron emission tomography for lymphnode staging in non-small-cell lung cancer? (2000) (45)
Long-term follow-up of metabolic activity in human alveolar echinococcosis using FDG-PET (2008) (44)
Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells (2003) (44)
Accurate Preoperative Localization of Parathyroid Adenomas With C-11 Methionine PET/CT (2013) (44)
In vivo assessment of phagocytic properties of Kupffer cells. (1981) (42)
Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases. (2011) (42)
Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities. (2002) (42)
Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer. (2012) (41)
Lymph node staging in lung cancer using [18F]FDG-PET. (2004) (40)
Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model (2010) (40)
Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells (2003) (39)
Radiofluorination of PSMA-HBED via Al18F2+ Chelation and Biological Evaluations In Vitro (2015) (39)
C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism. (2010) (39)
Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? (2000) (38)
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging (2003) (38)
Improved non-invasive T-Staging in non-small cell lung cancer by integrated18F-FDG PET/CT (2007) (38)
Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. (2006) (38)
Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma (2007) (37)
123I-phenylpentadecanoic acid as a tracer of cardiac free fatty acid metabolism. Experimental and clinical results. (1985) (37)
Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells (2003) (37)
Recent advances in bone marrow scanning (2005) (37)
Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography. (2014) (36)
[Lymph node staging of bladder neck carcinoma with positron emission tomography]. (1999) (35)
Positron emission tomography for detection and staging of malignant lymphoma. (2000) (33)
[18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? (2004) (33)
Assessment of Regional Myocardial Uptake and Metabolism of ω-(p-123I-Phenyl) Pentadecanoic Acid with Serial Single-Photon Emission Tomography (1982) (32)
Radiosynthesis of a new PSMA targeting ligand ([18F]FPy-DUPA-Pep). (2011) (32)
CD34+ cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients (2004) (32)
Is 3′-deoxy-3′-18F-fluorothymidine a better marker for tumour response than 18F-fluorodeoxyglucose? (2006) (32)
Cellular origin and molecular mechanisms of 18F-FDG uptake: is there a contribution of the endothelium? (2004) (31)
Captopril mediated decrease of aortic regurgitation. (1985) (31)
Improving Anti-CD45 Antibody Radioimmunotherapy Using a Physiologically Based Pharmacokinetic Model (2009) (31)
Use of integrated FDG-PET/CT in sarcoidosis. (2008) (30)
Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep (2014) (30)
Quantitative imaging of yttrium-86 PET with the ECAT EXACT HR+ in 2D mode. (2004) (29)
Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions (2013) (29)
Disturbed neural circuits in a subtype of chronic catatonic schizophrenia demonstrated by F-18-FDG-PET and F-18-DOPA-PET (2001) (28)
Internal radionuclide therapy: The ULMDOS software for treatment planning. (2005) (27)
123I-ITdU–Mediated Nanoirradiation of DNA Efficiently Induces Cell Kill in HL60 Leukemia Cells and in Doxorubicin-, β-, or γ-Radiation–Resistant Cell Lines (2007) (27)
Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. (2012) (26)
False-positive FDG PET in patients with pancreatic masses: an issue of proper patient selection? (1998) (26)
Cardiac metabolism of omega-(p-iodo-phenyl)-pentadecanoic acid: a gas-liquid chromatographic-mass spectrometric analysis. (1984) (26)
Comparing time activity curves using the Akaike information criterion (2009) (26)
Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment (1999) (25)
Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors (2010) (24)
A survey of PET activity in Germany during 1999 (2002) (23)
Usefulness of FDG-PET in diagnosing primary lymphoma of the liver. (1997) (23)
Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatised thymidine analog. (2006) (22)
One pot radiofluorination of a new potential PSMA ligand [Al18F]NOTA‐DUPA‐Pep (2012) (22)
Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study. (2006) (22)
Internal radionuclide therapy: the ULMDOS software for treatment planning. (2005) (22)
Simultaneous iterative reconstruction of emission and attenuation images in positron emission tomography from emission data only. (2002) (22)
Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma (2007) (22)
Relation of Myocardial Blood Flow and Initial Cardiac Uptake of 15-(p-123I-Phenyl)-Pentadecanoic Acid in the Canine Heart (1984) (22)
In vivo evaluation of 5-[(18)F]fluoro-2'-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model. (2001) (21)
Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation. (2006) (21)
[18F]FDG-PET in Patients with Alzheimer’s Disease: Marker of Disease Spread (2004) (21)
Brief S2k guidelines – Merkel cell carcinoma (2013) (21)
99Tcm-methoxy-isobutyl-isonitrile SPECT to evaluate a perfusion index from regional myocardial uptake after exercise and at rest. Results of a four hour protocol in patients with coronary heart disease and in controls. (1990) (20)
[F-18-FDG PET for primary diagnosis differential diagnosis of pleural processes]. (1999) (20)
F-18 Fluorodeoxyglucose (FDG) and C-Reactive Protein (CRP). (1999) (20)
Treatment of radioactive decay in pharmacokinetic modeling: influence on parameter estimation in cardiac 13N-PET. (1999) (20)
Simultaneous iterative reconstruction for emission and attenuation images in positron emission tomography. (2000) (20)
Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy (2015) (20)
Adenovirus-delivered siRNA. (2004) (20)
Functional imaging of neuroendocrine tumours with PET (2006) (19)
67Ga scintigraphy: procedure guidelines for tumour imaging (2003) (19)
[11C]Choline-PET/CT for outcome prediction of salvage radiotherapy of local relapsing prostate carcinoma. (2012) (19)
New diagnostic imaging procedures in Hodgkin's disease. (1996) (19)
Reproducibility of a single-sample method for 99Tcm-MAG3 clearance under clinical conditions. (1997) (18)
Targeting bcl-2 by triplex-forming oligonucleotide--a promising carrier for gene-radiotherapy. (2003) (18)
Optimal preloading in radioimmunotherapy with anti-cD45 antibody. (2011) (18)
Metabolism of 15 (p123I iodophenyl-)pentadecanoic acid in heart muscle and noncardiac tissues (2004) (18)
Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. (2012) (18)
A comparison of the biodistribution and biokinetics of 99mTc-anti-CD66 mAb BW 250/183 and 99mTc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy (2003) (18)
Triplex forming oligonucleotide targeted to 3'UTR downregulates the expression of the bcl-2 proto-oncogene in HeLa cells. (2001) (17)
Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling. (2010) (17)
[Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results]. (1995) (17)
FDG PET for imaging pericardial manifestations of Hodgkin lymphoma. (2003) (17)
Endovascular irradiation with the liquid beta-emitter Rhenium-188 to reduce restenosis after experimental wall injury. (2001) (16)
Intracoronary beta-irradiation with a liquid (188)re-filled balloon: six-month results from a clinical safety and feasibility study. (2000) (15)
Pro-apoptosis and anti-proliferation effects of a recombinant dominant-negative survivin-T34A in human cancer cells. (2009) (15)
[Preoperative assessment of asymptomatic adnexal tumors by positron emission tomography and F 18 fluorodeoxyglucose]. (1999) (15)
New molecular markers for prostate tumor imaging: a study on 2-methylene substituted fatty acids as new AMACR inhibitors. (2011) (15)
Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease. (2010) (15)
[Imaging of the normal skeletal system with 18F Na-PET compared with conventional skeletal scintigraphy using Tc99m-MDP]. (1998) (15)
[18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation. (2003) (14)
Preferential Tumor Targeting and Selective Tumor Cell Cytotoxicity of 5-[131/125I]Iodo-4′-Thio-2′-Deoxyuridine (2008) (14)
Fluoro-3-Deoxythymidine ( [ 18 F ]-FLT ) as Positron Emission Tomography Tracer for Imaging Proliferation in a Murine B-Cell Lymphoma Model and in the Human Disease (2003) (14)
Possible site of the in vivo disposition of sodium nitroprusside in the rat (1982) (14)
[Dosimetry fundamentals of endovascular therapy using Re-188 for the prevention of restenosis after angioplasty]. (1998) (14)
Experimental basis of metabolic imaging of the myocardium with radioiodinated aromatic free fatty acids. (1986) (13)
Labelling of a monoclonal antibody with 68Ga using three DTPA-based bifunctional ligands and their in vitro evaluation for application in radioimmunotherapy (2007) (13)
Validation of myocardial blood flow estimation with nitrogen-13 ammonia PET by the argon inert gas technique in humans (2001) (13)
[PET and PET/CT in relapsing prostate carcinoma]. (2006) (13)
Impact of FDG-PET Computed Tomography for Surgery of Recurrent or Persistent Differentiated Thyroid Carcinoma (2012) (13)
Reticuloendothelial system Fc-receptor function in patients with immune thrombocytopenia after treatment with high dose intravenous immunoglobulin. (2009) (13)
Rhenium-188 Labeled Hydroxyapatite and Rhenium-188 Sulfur Colloid (1997) (13)
Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma (2007) (12)
Diagnostic accuracy of intraoperative perfusion-weighted MRI and 5-aminolevulinic acid in relation to contrast-enhanced intraoperative MRI and 11C-methionine positron emission tomography in resection of glioblastoma: a prospective study (2018) (12)
Dosimetry with (188)Re-labelled monoclonal anti-CD66 antibodies. A simplified approach based on a single measurement 3 h p.i. (2006) (12)
Lymph node staging for urinary bladder carcinoma with positron emission tomography (PET) (2016) (12)
Cardiac metabolism of 15 (p-I-123 phenyl-) pentadecanoic acid after intracoronary tracer application. (1984) (12)
Activation of intrinsic apoptotic pathway by Re-188 irradiation and paclitaxel in coronary artery smooth muscle cells. (2008) (11)
Internal radionuclide therapy (2006) (11)
Quantification of 18F-FDG uptake in non-small cell lung cancer: a feasible prognostic marker? (2004) (11)
Auger electron emitter against multiple myeloma--targeted endo-radio-therapy with 125I-labeled thymidine analogue 5-iodo-4'-thio-2'-deoxyuridine. (2011) (10)
Novel imaging techniques in NHL: Clinical results with PET imaging (2001) (10)
Liposomal delivery of antisense oligonucleotides for efficient downregulation of Bcl-2 and induction of apoptosis. (2002) (10)
Bone marrow immunoscintigraphy compared with conventional bone scintigraphy for the detection of bone metastases. (1993) (10)
Performance of Integrated FDG-PET/CT for Differentiating Benign and Malignant Lung Lesions - Results from a Large Prospective Clinical Trial (2008) (10)
Short Communication: (18)F-immuno-PET: Determination of anti-CD66 biodistribution in a patient with high-risk leukemia. (2008) (10)
Single photon emission tomography imaging of myocardial oxidative metabolism with 15-(p-[123I]iodophenyl) pentadecanoic acid in patients with coronary artery disease and aorto-coronary bypass graft surgery (2004) (10)
ROC analysis for assessment of lesion detection performance in 3D PET: influence of reconstruction algorithms. (2003) (9)
[Reduction of regurgitation in aortic and mitral insufficiency by captopril in acute and long-term trials]. (1985) (9)
Intracoronary β-brachytherapy using a rhenium-188 filled balloon catheter in restenotic lesions of native coronary arteries and venous bypass grafts (2006) (9)
Effect of myocardial perfusion and metabolic interventions on cardiac kinetics of phenylpentadecanoic acid (IPPA) I 123 (2004) (9)
Improving binding potential analysis in [11C]raclopride PET studies using cluster analysis. (2004) (9)
FDG-PET and PET/CT in malignant lymphoma. (2008) (8)
Kinetics of 17-(123I) iodoheptadecanoic acid in myocardium of rats (1983) (8)
Synthesis and Biologic Study of IV-14, a New Ribonucleoside Radiotracer for Tumor Visualization (2009) (8)
1011-116 Myocardial Rb Extraction Fraction: Determination in Humans (1995) (8)
Iterative reconstruction for attenuation correction in positron emission tomography: maximum likelihood for transmission and blank scan. (1999) (8)
Experimental and clinical experience with iodine 123-labeled iodophenylpentadecanoic acid in cardiology (1994) (8)
Synthesis and labelling of Df-DUPA-Pep with gallium-68 and zirconium-89 as new PSMA ligands (2014) (8)
Dosimetrie Fundamentals of Endovascular Brachytherapy Using Re-188 to Prevent Restenosis after Angioplasty (1998) (8)
Radiosynthesis of [18F]FEt-Tyr-urea-Glu ([18F]FEtTUG) as a new PSMA ligand (2013) (7)
Radiation dosimetry and biodistribution of the beta-amyloid plaque imaging tracer 11C-BTA-1 in humans (2007) (7)
Patients with in-stent restenoses (2007) (7)
Reduced technetium 99m labelled NCA-95/CEA-antibody uptake in liver due to gentle antibody reconstitution (2004) (7)
Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of β-amyloid plaques (2007) (7)
A 25-year-old woman with a gastric GIST and a PET-positive epicardial tumor (2007) (7)
Clinical Value of Positron Emission Tomography (PET) in Oncology: Results of an Interdisciplinary Consensus Conference (1996) (7)
Familial acanthocytosis with paroxysmal exertion-induced dyskinesias and epilepsy (FAPED) (2004) (7)
Determination of the immunoreactivity of radiolabeled monoclonal antibodies: a theoretical analysis. (2006) (6)
Dependence of the anti-CD66 antibody biodistribution on the dissociation constant: a simulation study. (2011) (6)
Performance of Integrated FDG-PET/CT for Differentiating Benign and Malignant Lung Lesions -Results from a Large Prospective Clinical Trial (2008) (6)
Analysing saturable antibody binding based on serum data and pharmacokinetic modelling (2011) (6)
Synthesis of 15-(4-[131I]iodophenyl)pentadecanoic acid (p-IPPA) via tin-precursor using Chloramine-T as an oxidant (2010) (6)
[Nuclear imaging of prostate cancer: current status]. (2007) (6)
[Positron-emission tomography in the diagnosis of abdominal tumors]. (1998) (6)
Modelling radioimmunotherapy with anti-CD45 antibody to obtain a more favourable biodistribution (2009) (5)
pore-expanded mesoporous silica nanoparticles for PET (2014) (5)
[Cause of crossed cerebellar diaschisis in cerebrovascular disease]. (1984) (5)
Radioiodinated methyl-branched fatty acids: Evaluation of catabolites formed in vivo (1987) (5)
Elevated FDG uptake in the lactating human breast. (2001) (5)
[Detection of bone involvement in malignant diseases by immunoscintigraphy of the bone marrow]. (1993) (4)
Brain Imaging: The Chemistry of Mental Activity (2009) (4)
Determination of individual organ masses for (90)Y-anti-CD66 radioimmunotherapy: influence on therapy planning. (2011) (4)
Sustained I-131 phenylpentadecanoic acid (IP) uptake in salvaged myocardium (1984) (4)
Biodistribution, cellular uptake and DNA-incorporation of the 2'-fluoro stabilized 5-iodo-2'-deoxyuridine analog 5-iodo-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil (FIAU). (2008) (4)
[Neurinoma of the recurrent laryngeal nerve--as a case report, an argument for nerve preparation]. (1989) (4)
Metronomic Treatment with Low-Dose Trofosfamide Leads to a Long-Term Remission in a Patient with Docetaxel-Refractory Advanced Metastatic Prostate Cancer (2010) (4)
Synthesis of 15-(4-[11C]methylphenyl)pentadecanoic acid (MePPA) via Stille cross-coupling reaction (2011) (4)
Chromosome instability and tumor lethality suppression in carcinogenesis (2008) (3)
[For the benefit of the patient: the sentinel node excision]. (2011) (3)
[Prerequisites for diagnostic use of antisense oligonucleotides in nuclear medicine]. (1996) (3)
Both total chain length and position of dimethyl-branching effect the myocardial uptake and retention of radioiodinated analogues of 15-(p-iodophenyl)-3,3-dimethylpentadecanoic acid (DMIPP) (1996) (3)
[Reduced myocardial fatty acid utilization in coronary heart disease following symptom limited ergometric stress. Detection of pathologic metabolic patterns using iodine-123-phenylpentadecanoic acid and sequential SPECT]. (1989) (3)
Pathophysiological Basis and Clinical Value of 18F-Fluorodeoxyglucose and Positron Emission Tomography in Pancreatic Adenocarcinoma (1994) (3)
Detection of Skeletal Involvement in Malignant Disease by Immunoscintigraphy of Bone Marrow (1993) (3)
Myeloablative radioimmunotherapy with 188Re-CD66mAb before stem cell transplantation (2009) (3)
Catabolism of 15-(p-lodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) by isolated rat hearts (2004) (3)
On the Occurrence of Crossed Cerebellar Diaschisis in Cerebrovascular Disease (1984) (3)
Prerequisites for the Use of Antisense Oligonucleotides in Nuclear Medicine (1996) (3)
Cancer Model for Positron Emission Tomography in a Murine Pancreatic-deoxyuridine as Tracer ′ F ] Fluoro-218 Evaluation of 5-[ In Vivo (2001) (3)
Sodium Nitroprusside: Indication that Peripheral Vascular Beds are the Sites for its Rapid in Vivo Inactivation (1981) (3)
Production of Zr-89 on a PETtrace cyclotron (2013) (3)
Myeloablative Radioimmuntherapie mit 188Re-CD66mAb vor Stammzelltransplantation: Kein Anstieg proinflammatorischer Zytokinspiegel von TNF-α (2008) (3)
Hyperthermia: Different Methods, Different Aims, and Different Problems (1999) (3)
[Advancement of PET and PET/CT in prostate carcinoma]. (2006) (3)
Corrigendum to “Delusional infestation: Neural correlates and antipsychotic therapy investigated by multimodal neuroimaging” [Prog. Neuropsychopharmacol. Biol. Psychiatry 34 (2010) 1215–1222] (2012) (3)
68Ga-DOTA-DUPA-Pep as a new peptide conjugate for molecular imaging of prostate carcinoma (2011) (3)
The Bone Scan in Osteomyelosclerosis (2001) (3)
[Positron emission tomography of the skeletal system using 18FNa: frequency, distribution and appearance of skeletal metastases]. (1999) (3)
1019: Clinical Value of [11C] Choline Petict in Patients with Rising PSA After Primary Treatment of Prostate Cancer (2007) (2)
[Simulation of a mediastinal non-Hodgkin lymphoma recurrence by a diffuse thymus hyperplasia in 18F-FDG PET scan]. (1996) (2)
Kinetic investigations of the electrophilic N.C.A. radioiodination of 2′‐deoxyuridine using iodogenTM (2001) (2)
Radiosynthesis of [90Y]DOTA-DUPA-Pep for clinical applications (2014) (2)
Intracoronary b -Irradiation With a Liquid 188 Re-Filled Balloon Six-Month Results From a Clinical Safety and Feasibility Study (2000) (2)
Iterative image reconstruction reduces apparent tumor distortion. (1997) (2)
[Reduction of regurgitation in aortic insufficiency by inhibition of the renin-angiotensin converting enzyme]. (1984) (2)
Towards to hENT1-nucleoside transporter selective imaging agents. Synthesis and in vitro evaluation of the radiolabeled SAENTA analogues. (2009) (2)
Myeloablative radioimmunotherapy with Re-188 labeled anti-CD66-mAB prior to stem cell transplantation of leukemia patients: Correlation of bone marrow dose and engraftment as well as probability of relapse (2001) (2)
Cardiac metabolism of I-123 phenyl-pentadecanoic acid (1987) (2)
[Single-photon emission computed tomography (SPECT) of the liver with a rotating gamma camera system (author's transl)]. (1981) (2)
Positron Emission Tomography with 18-F-Fluorodeoxyglucose in the Staging and Follow-Up of Lymphoma: Status quo and quo vadis (1999) (2)
Complete dopamine D2 receptor occupancy without extrapyramidal side effects under benperidol. (2004) (2)
[Positron-emission tomography of the skeletal system using 18FNa: the incidence, pattern of the findings and distribution of benign changes]. (1998) (1)
Binding affinity and kinetic analyses of modifications of urea-based PCa tracers (2014) (1)
F-18-FDG-PET for Differential Diagnosis of Pleural Processes (1999) (1)
Intrathoracic metastatic spread of parathyroid carcinoma (2010) (1)
Auger-electron-DNA-targeted therapy breaks chemo- and radioresistance in leukemia cells (2007) (1)
Positron emission tomography (PET): Diagnostic benefit in pancreatic tumors? (1997) (1)
Viability as seen with radiolabelled fatty acids — a new approach to a challenqinq problem (1994) (1)
Diagnostic effectiveness, cost-effectiveness and prognostic utility of PET/CT in non-small cell lung cancer (NSCLC) (2008) (1)
Comparative evaluation of labelling patterns and turnover of lipids, tagged by 15 /p-123I-phenyl-/ pentadecanoic and 1-14C-palmitic acid (1984) (1)
New solid state target construction on a PETtrace cyclotron (2013) (1)
Improved Synthesis and in Vitro Stability Test of Rhenium-188 Labeled Radiopharmaceuticals for Potential Use in Radiation Synovectomy (1997) (1)
[Current status of positron emission tomography in diagnosis of abdominal tumors]. (1999) (1)
1816: 11C-Cholin-Pet/Ct a new Image Modality in Prostate Cancer Detection (2004) (1)
Heterozygous R1101K mutation of the DCTN1 gene in a family with amyotrophic lateral sclerosis and frontotemporal dementia (2005) (1)
Radioimmunotherapy for Myeloablation Before SCT in Paediatric Patients with Malignant and Non-Malignant Diseases. (2007) (1)
Myeloablative radioimmunotherapy with Re-188-labeled anti-CD66a,b,c,e-antibody for conditioning of high-risk ALL and CML patients prior to stem cell transplantation (2000) (1)
Captopril-induced reduction of regurgitation fraction in aortic insufficiency: Acute and long-term effects (1985) (1)
PET Assessment of Lymphoma: Beyond (18)F-Fluorodeoxyglucose. (2006) (1)
[18F]Dihydroxyphenylalanine-PET/CT in pheochromozytoma (2007) (1)
Assessment and Quantification of Regional Arterial Perfusion Reserve in Patients with Peripheral Occlusive and Small-Vessel Disease by Rubidium 82-Positron Emission Tomography (1996) (1)
Indikationen der modernen PET/CT-Diagnostik (2013) (1)
[The noninvasive determination of resting myocardial blood flow in patients using 82 Rb in comparison with the argon method]. (1993) (1)
Synthesis and biodistribution of 3'-fluoro-5-[(131)I]iodo-2'-deoxyuridine: a comparative study of [(131)I]FLIdU and [(18)F]FLT. (2007) (1)
Detection of local recurrence by means of 11-C-Choline-PET/CT after radical prostatectomy for conformal radiation therapy (2003) (1)
Radiosynthesis of carbon-11 labeled 6-methyldopamine ([¹¹C]MeDA). (2012) (1)
Mono- and dimethylbenzyls as new protecting groups for no-carrier-added nucleophilic aromatic radiofluorination (2011) (1)
1011-117 Comparison of 82Rubidium Positron Emission Tomography to 99Technetium-Methoxyisobutyl Isonitrile Perfusion Imaging (1995) (1)
856 11C-Choline-PET/CT determines potentially curative patients with prostate cancer recurrencies (2003) (1)
259Lymph node staging in prostate cancer by the use of 11C-choline-PET/CT scan imaging (2005) (1)
Radioimmunotherapy with Re-188 labelled anti-CD66 antibody for myeloablation prior to stem cell transplantation in high risk leukemia patients (2000) (0)
[Results of fatty acid SPECT of the myocardium in coronary disease]. (1986) (0)
Auger-electron-emitter labelled triplex forming oligonucleotides form stable triple helices and inhibit transcription in vitro (2001) (0)
Elevated Expression of Glucose Transporter Genes as Reason for an Increased F-18 FDG Uptake in Human Pancreatic Adenocarcinoma (1997) (0)
Localization of residual disease in medullary thyroid carcinoma by integrated 18F-DOPA PET / CT (2006) (0)
Coronary Artery Disease (CAD): ROC-Analysis of Tc-99m-MIBI-SPECT Versus Rb-82-PET (1997) (0)
10-9 Total sleep deprivation and cerebral glucose utilization in depression (1997) (0)
Uptake and metabolism of N-13-ammonia in SCID mouse xenografts (2011) (0)
855 Detection of local recurrence by means of 11C-Choline-PET/CT after radical prostatectomy for conformal radiation therapy (2003) (0)
[The importance of PET in searching the primary tumor site in CUP patients -- a case report]. (2005) (0)
Radioresistance to yttrium-90 and gamma-irradiation depends on DNA-double-strand-break repair (2007) (0)
Non-Invasive Detection of Resting Myocardial Blood Flow with 82Rb PET in Patients Compared to the Argon Method (1993) (0)
TABLE 1 Number of Patients with FDG PET and Bone Scintigraphy in 56 (2006) (0)
Dosimetry with 188Re-labelled monoclonal anti-CD66 antibodies (2006) (0)
An attractive approach for HPLC detection of both β+/β- emitters (2011) (0)
854 Postoperative dilemma of rising PSA levels in patients with prostatectomy: Evaluation of 11C-Choline-PET/CT examination for radiation therapy (2003) (0)
Synthesis and biological evaluation of the new radioiodinated pyrimidine nucleosides (2007) (0)
Turnover of lipids labeled by I-123 phenylpentadecanoic acid (IP) compared to C-14 palmitic acid (P) (1984) (0)
In vivo amyloid imaging with the new radiotracer [N-Methyl-11C]2-(4'-(methylamino)phenyl)-benzothiazol (C-11-BTA-1) in Alzheimer's disease (2006) (0)
Differences in predicted and actually absorbed doses in sst2 targeting peptide therapy (2012) (0)
Preparation of 15-(4-[11C]methylphenyl)pentadecanoic acid (MePPA) as a new tracer for studies in animal models (2011) (0)
Antigene effects of bcl-2 targeting triple helix-forming oligonucleotides in human lymphoma cells (2001) (0)
Synthesis of no-carrier-added 6-[11C]methyl-l-DOPA (2012) (0)
Physiologically based pharmacokinetic (PBPK) model for CD45-antibody radioimmunotherapy (RIT) with preloading (2008) (0)
Reliable Diagnosis of Pancreatic Adenocarcinoma with 18-F-2-FDG-Positron-Emission-Tomography (PET) (1995) (0)
FDG-PET in staging primary gastrointestinal lymphoma (1998) (0)
Prediction of axillary lymphatic node status in primary breast cancer — Comparison between positron emission tomography (PET) and sentinel-node biopsy (1998) (0)
[Vasodilating-acting antihypertensive agents: model substance sodium nitroprusside]. (1977) (0)
31st Annual Meeting of the German Association of Endocrine Surgeons (CAEK) (2012) (0)
Kinetics of Radioiodinated Isopropylamphetamine in Blood and Brain (1985) (0)
Radioiodinated fenetylline (captagon): A new potential brain imaging agent (1984) (0)
PET in Abdominal Imaging of Tumors and Infections (1999) (0)
European Association of Nuclear Medicine Congress 10–14 October 1993, Lausanne, Switzerland (2004) (0)
Synthesis, radiolabeling and biological evaluation of new iodo-vinyl-pyrimidine nucleosides (2007) (0)
Efficient radiosynthesis of a new PSMA ligand: [Al18F]DTPA-CHX-DUPA-Pep (2014) (0)
PET/CT for restaging breast cancer - Impact on patient management and patient outcome (2008) (0)
Accurate diagnosis of pancreatic carcinoma with positron-emission-tomo-graphy (PET) and fluoro-18-2-deoxy-D-glucose (FDG) (1996) (0)
Bestimmung der regionalen Herzmuskelaufnahme und des Stoffwechsels von oo-mJ-Paraphenylpentadecansäure mittels der sequentiellen Single-Photon-Emissionstomographie (1982) (0)
SPECT of the Brain Using Radiolabeled Amphetamines and a Rotating Gamma Camera (1985) (0)
Determination of the Myocardial Rubidium Extraction Fraction: Theoretical Investigation (1997) (0)
FDG-PET and PET/CT in Pancreatic Cancer (2008) (0)
Synthesis and preclinical study of IV-14 - New radioiodinated ribonucleoside (2008) (0)
[11C]Methylation of dopamine as a new tracer for preclinical studies (2011) (0)
Synthesis of no-carrier-added 6-[C-11]methyl-L-DOPA (2012) (0)
One pot radiosynthesis of a new PSMA ligand [Al18F]NOTA-DUPA-Pep (2012) (0)
Preoperative Thoracic Staging of Non-Small Cell Lung Cancer: 18-FDG-PET Evaluation (1997) (0)
Monte Carlo Modeling of the Effects of Cascade Gamma Photons in 2D PET Images Obtained With the Isotopes: Br (2009) (0)
A new ribonucleoside radiotracer for tumor visualization and radiotherapy: Synthesis and biological study (2009) (0)
The Metabolism of Radioiodinated Free Fatty Acids in the Heart. Physiological Basis and Cardiac Biokinetics (1985) (0)
Inhibition of cell cycle progression and induction of apoptosis in a human lung carcinoma cell line mediated by survivin-specific triplex forming oligonucleotides (2002) (0)
Model selection and parameter inference for sparse pharmacokinetic data: Efficacy of the Akaike Information Criterion (AICc) and the F-test (2008) (0)
[Detection of bone marrow involvement in breast cancer and malignant lymphoma using immunoscintigraphy of the hematopoietic bone marrow]. (1990) (0)
Zr-89 labeling of mesoporic silica based nanoparticles (2014) (0)
Intensification of the Conditioning Regimen for Patients with high-risk AML and MDS: 3 year Experience of using an188 Re — Labelled anti — CD 66 Monoclonal Antibody (2003) (0)
95 New PET-Tracers for imaging pathophysiology and response (2009) (0)
Radioimmunotherapy (RIT) with anti-CD45 antibody: Optimal timing of the preload (2009) (0)
264C-11 choline-PET/CT in primary localised prostate cancer: A comparison of a non-invasive method vs. surgery (2005) (0)
Optimizing radioimmunotherapy with anti-CD66 antibody using physiologically based pharmacokinetic (PBPK) modeling (2009) (0)
[Significance of PET for ENT-tumors]. (2004) (0)
Artifacts in Reconstructed PET-Images Due to Variation in Detector Sensitivity (1997) (0)
Radiofluorination and docking studies for [18F]FEt-Tyr-urea-Glu ([18F]FEt-TUG) as a new potential PSMA ligand (2013) (0)
[SPECT (201T1) of the myocardium after experimental infarction]. (1982) (0)
Tc-99m-Sestamibi Whole-Body Distribution after Stress Testing with Arbutamine and Dipyridamole: a Comparison with Resting Condition (1997) (0)
1596: Lymph Node Staging in Prostate Cancer by the use of 11C-CHOLIN-PET/CT Scan Imaging (2005) (0)
Imaging of prostate carcinoma using PSMA-addressing peptide conjugates (2012) (0)
– Prostate Cancer New Clinical Indications for 18 F / 11 C-choline , New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging : A Systematic Review of the Literature (2016) (0)
1531: Visualisation of Local Recurrence after Definite Prostate Cancer Treatment by the use of 11C-CHOLIN-PET/CT (2005) (0)
Noninvasive Determination of the Arterial Input Function: General Description for an Artery Surrounded by Homogeneous Tissue (1995) (0)
Overcoming chemoresistance and radioresistance in leukemia cells using Bi-213 labeled anti-CD45 monoclonal antibody (2006) (0)
Phonological and visuospatial working memory: A common network and sources of lateralization (2001) (0)
[18F]-Labeling in substituted 2-nitropyridine as a surrogate for benzene in radiopharmaceuticals (2011) (0)
Preferential tumor targeting and selective cytotoxicity of 5-[131/125I]-iodo-4'-thio-2'-deoxyuridine (2008) (0)
Internal radionuclide treatment planning using tomographic data: The extended ULMDOS software (2006) (0)
Efficient labeling procedure for triplex forming oligonucleotides with the Tc-99m-tricarbonyl-complex (2002) (0)
Radiolabeled DNase, a potential indicator for noninvasive detection of tissue damage (2004) (0)
Modeling Radioimmunotherapy with Anti-CD20 Antibody – Optimal Preload Depending on Lymphoma Transcapillary Solute Exchange (2009) (0)
COMBINED 11C-CHOLINE POSITRON EMISSION TOMOGRAPHY/ COMPUTER TOMOGRAPHY (11C-CHOLINE PET/CT) FOR THE EVALUATION AFTER HIGH INTENSITY ULTRASOUND (HIFU) TREATMENT IN LOCALISED PROSTATE CANCER (2008) (0)
Synthesis of the new tracer L-6-[11C]methyl-DOPA (2011) (0)
Analysis of the molecular pathways of Bi-213 bound to anti-CD45-induced cell death in comparison to the molecular pathways of Y-90 bound to anti-CD45-induced cell death (2007) (0)
PET Imaging of Breast Cancer Molecular Biomarkers (2008) (0)
15(p-['231]Iodophenyl)Penadecanoic Acid as Tracer of Lipid Metabolism: Comparisonwith [1-'4C]PalmiticAcid in MurineTissues (2006) (0)
Viability as seen with radiolabelled fatty acids — a new approach to a challenqinq problem (2004) (0)
Synthesis and labeling of CHX-A''-DTPA-DUPA-Pep with gallium-68, zirconium-89 and lutetium-177 for diagnosis and therapy of prostate cancer (2014) (0)
Integrated 11C-methionine PET / CT to detect occult residual parathyroid cancer (2006) (0)
Comparison of parametric contrast enhanced ultrasound (SonoVue®) with quantified F-18-FDG-PET-CT in determining the vitality of liver lesions by hepatic alveolar echinococcosis (2013) (0)
[18F]FPy-DUPA-Pep as a new ligand for PSMA-specific imaging of prostate cancer (2011) (0)
[Localization of pre-excitation in the WPW syndrome by analysis of the ventricular contraction course]. (1985) (0)
Myeloablative radioimmunotherapy: Comparison of biodistribution and biokinetics of Tc-99-anti-CD66-mAb vs. Tc-99-anti-CD45-mAb (2001) (0)
Comparison of kinetics between I-123-heptadecanoic acid (IHDA), I-125-phenylpentadecanoicacid (IPPA) and I-131-dimethylphenylpentadecanoic acid (DMIPPA), in the normal dog heart (1987) (0)
Physiologically based pharmacokinetic modeling: Investigating bivalent antibody-antigen interaction (2009) (0)
Cardiac radionuclide imaging. (1989) (0)
Cost-effectiveness of anatometabolic imaging with PET/CT for staging of NSCLC (2009) (0)
Comparison of the blood serum biokinetics of In-111 and Y-90 labelled antibodies using an information theoretic approach (2007) (0)
Is there a role for dose painting within the prostate in the primal therapy of patients with localized prostate cancer using choline PET/CT, dynamic MRI and CAD or choline MRS? (2010) (0)
67 poster: 18F-FDG PET/CT as a Selection Tool for Image Guided Radiotherapy (IGRT) in Patients with Recurrent or Residual Ovarian Cancer (2010) (0)
Synthesis and labeling of DOTA-SOM230 conjugates (2007) (0)
[Whole body distribution of Tc-99m-sestamibi after pharmacological stress with arbutamine and dipyridamole compared with resting conditions]. (1997) (0)
Therapy for Patients with Rectal Carcinoma (1999) (0)
In comparison to F18-sodium fluoride PET the extent of metastatic bone disease is underestimated with FDG in lung cancer patients (2007) (0)
2-Methylen substituted fatty acids (2-MFAs) as potential AMACR-specific tracers. Synthesis and in vitro study (2010) (0)
1957: Visualisation of Rising PSA after RPX by the Use of 11C-Cholin-PET/CT (2004) (0)
[PET in pancreatic tumor of unknown origin--luxury or value?]. (1997) (0)
Diagnosis — Methods for Evaluating Myocardial Microcirculation in Patients (1982) (0)
Investigating the relevance of saturable binding in radioimmunotherapy using pharmacokinetic modeling (2010) (0)
Evaluation of mRNA Targeting by Labeled Oligonucleotides for Tumor-Diagnosis (1999) (0)
Evaluation of f-18-fdg pet/ct in patients suspected of local recurrence of colorectal cancer introduced to external conformal radiotherapy (2004) (0)
A Method for Determination of Regional Myocardial Blood Flow (RMBF) Considering Regional Spillover (1995) (0)
An attractive approach for HPLC detection of both {beta}+/{beta}- emitters (2011) (0)
Increased renal toxic effect of total body irradiation in combination with radioimmunotherapy (2001) (0)
[Experimental myocardial infarct in computerized tomography]. (1982) (0)
54 poster: Is there a Role for dose Painting within the Prostate in the Primal Therapy of Patients with Localized Prostate Cancer using Choline PET/CT, Dynamic MRI and CAD or Choline MRS? (2010) (0)
S2073 18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHIC IMAGING OF INFLAMMATORY DISEASE AFTER TOTAL KNEE REPLACEMENT (2004) (0)
Early D etection a nd A ccurate D escription o f E xtent o f Metastatic B one D isease i n B reast C ancer W ith F luoride Ion a nd P ositron E mission T omography (1999) (0)
Structural and functional abnormalities of the brain in myotonic dystrophy type 1 (MD1) and 2 (MD2) (2008) (0)
Molecular imaging of leukemia with FLT-PET (2007) (0)
In vivo studies of a 5-[I-131/125]-iodo-4'-thio-2'-deoxyuridine in a HL60-xenograft mouse model: Effects of the thymidylate synthase inhibitor 5-fluoro-2'-deoxyuridine (2007) (0)
Subject Index Vol. 11, 1994 (1994) (0)
Diagnosis ofpancreatic cancer by 2(18F) -fluoro-2-deoxy- D-glucose emission tomography (1995) (0)
Polytrauma-CT – Goldstandard ohne Standard? (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sven Norbert Reske?

Sven Norbert Reske is affiliated with the following schools:

University of Ulm

Sven Norbert Reske's Academic­Influence.com Rankings

Sven Norbert Reske's Degrees

Why Is Sven Norbert Reske Influential?

Sven Norbert Reske's Published Works

Published Works

What Schools Are Affiliated With Sven Norbert Reske?

Sven Norbert Reske's AcademicInfluence.com Rankings